What is Biosceptre?
Biosceptre is an innovative biotechnology firm dedicated to advancing cancer treatment through pioneering CAR T technology. The company's proprietary BRiDGECAR system is designed to target multiple antigens, offering a potential therapeutic solution for a broad spectrum of liquid and solid tumors. This advanced approach aims to enhance patient outcomes and establish best-in-class treatments for millions affected by various malignancies.
How much funding has Biosceptre raised?
Biosceptre has raised a total of $16M across 3 funding rounds:
Unspecified
$4.7M
Private Equity
$671K
Series A
$10.7M
Unspecified (2014): $4.7M, investors not publicly disclosed
Private Equity (2015): $671K, investors not publicly disclosed
Series A (2017): $10.7M supported by Tuspark Science and Technology Service Group
Key Investors in Biosceptre
Tuspark Science and Technology Service Group
Tus-Holdings Co., Ltd. is a large integrated enterprise established in reliance on Tsinghua University, focusing on developing, constructing, operating, and managing science parks. It is a significant investor in technology and innovation enterprises.
What's next for Biosceptre?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for Biosceptre. This capital infusion is expected to accelerate the development and clinical progression of its multiple CAR T programs. The company is poised to further its mission of delivering transformative cancer therapies, potentially expanding its market reach and solidifying its position in the competitive oncology landscape.
See full Biosceptre company page
